World's Best Scientists 2026 revealed!
Stephen D. Gillies

Stephen D. Gillies

D-Index & Metrics

Immunology

D-Index
73
Citations
15875
World Ranking
2159
National Ranking
1049

Overview

Stephen D. Gillies is affiliated with MSD in the United States and has contributed extensively to research primarily within the field of Medicine. Their work spans multiple specialized subfields including Oncology, Neurology, Immunology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The scientist's research focuses on several key topics, among which are:

  • Neuroblastoma Research and Treatments
  • CAR-T cell therapy research
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Cancer therapeutics and mechanisms
  • Alzheimer's disease research and treatments

Notable recent publications by Stephen D. Gillies include:

  • Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation (2020), published in Scientific Reports
  • Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma (2022), published in Theranostics
  • In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response (2020), published in Frontiers in Immunology
  • Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma (2022), published in Journal for ImmunoTherapy of Cancer
  • Short-course neoadjuvant in situ vaccination for murine melanoma (2022), published in Journal for ImmunoTherapy of Cancer

Most frequent co-authors collaborating with Stephen D. Gillies are:

  • Paul M. Sondel
  • Amy K. Erbe
  • Alexander L. Rakhmilevich
  • Zachary S. Morris
  • Taylor Aiken

The scientist regularly publishes in venues such as:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Scientific Reports
  • Theranostics
  • Frontiers in Immunology

Stephen D. Gillies' contributions across these journals illustrate a focus on immunotherapy, cancer biology, and neurodegenerative disease research. The combination of topics and multidisciplinary subfields represents an intersectional approach involving immunological mechanisms, clinical oncology, and neurology.

Best Publications

  • Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

    Leonard D. Shultz;Bonnie L. Lyons;Lisa M. Burzenski;Bruce Gott

  • Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis

    Karen S. Moulton;Khashayar Vakili;David Zurakowski;Mohsin Soliman

  • High-level expression of chimeric antibodies using adapted cDNA variable region cassettes.

    Stephen D. Gillies;Kin-Ming Lo;John Wesolowski

  • Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

    S D Gillies;E B Reilly;K M Lo;R A Reisfeld

  • Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

    A L Yu;M M Uttenreuther-Fischer;C S Huang;C C Tsui

  • A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

    R. Handgretinger;K. Anderson;P. Lang;R. Dopfer

  • Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

    B M Mueller;C A Romerdahl;S D Gillies;R A Reisfeld

  • Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Suzanne S. Shusterman;Wendy B. London;Stephen D. Gillies;Jacquelyn A. Hank

  • Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy

    Holger N. Lode;Rong Xiang;Torsten Dreier;Nissi M. Varki

  • Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow

    Holger N. Lode;Rong Xiang;Nissi M. Varki;Carrie S. Dolman

  • Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

    Mayumi Naramura;Stephen D. Gillies;John Mendelsohn;Ralph A. Reisfeld

  • T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.

    J C Becker;J D Pancook;S D Gillies;K Furukawa

  • A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

    Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan

  • Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

    Holger N. Lode;Thomas Moehler;Rong Xiang;Alfred Jonczyk

  • Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

    David M. King;Mark R. Albertini;Heidi Schalch;Jacquelyn A. Hank

  • Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.

    Stephen D. Gillies;John S. Wesolowski

  • NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

    Ruth Esser;Tina Müller;Dörthe Stefes;Stephan Kloess

  • A Dual-Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-Mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice

    Rong Xiang;F. James Primus;J. Michael Ruehlmann;Andreas G. Niethammer

  • Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

    Mansoor N. Saleh;M.B. Khazaeli;M.B. Khazaeli;Richard H. Wheeler;Laquetta Allen

  • Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

    David C. Delgado;Jacquelyn A. Hank;Jill Kolesar;David Lorentzen

  • Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2rγnull Mice Engrafted with Mobilized Human Hematopoietic Stem Cells.

    Leonard Shultz;Bonnie L. Lyons;Lisa M. Burzenski;Bruce Gott

Frequent Co-Authors

Ralph A. Reisfeld
Ralph A. Reisfeld Scripps Research Institute
Jacquelyn A. Hank
Jacquelyn A. Hank University of Wisconsin–Madison
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Rong Xiang
Rong Xiang Nankai University
David A. Cheresh
David A. Cheresh University of California, San Diego
Paul M. Sondel
Paul M. Sondel University of Wisconsin–Madison
Barbara M. Mueller
Barbara M. Mueller Torrey Pines Institute For Molecular Studies
Rupert Handgretinger
Rupert Handgretinger University of Tübingen
Jürgen C. Becker
Jürgen C. Becker University of Duisburg-Essen
Alice L. Yu
Alice L. Yu University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise in Immunology, several online degree options can open new career pathways in healthcare. One popular route is transitioning to advanced nursing roles, such as through an fnp to acnp bridge program online, which prepares family nurse practitioners to specialize in acute care settings.

Accelerated programs also offer a fast track to becoming a nurse practitioner. The accelerated np programs enable students with prior degrees to complete their nursing education efficiently while focusing on advanced practice skills critical in immunology-related fields.

For individuals without a nursing background, enrolling in online rn programs for non nurses provides a foundational pathway into nursing and healthcare, which can later lead to specialized immunology roles or advanced degrees.

Finally, understanding career prospects and compensation is vital. Exploring data on how much does a dnp make helps students plan their education and career pathway effectively, considering the return on investment in nursing and immunology-related careers.

Best Scientists Citing Stephen D. Gillies

Trending Scientists